Can NOW Supplements, Vitamin A & D3 25,000/1 help with Cancer?
' 
SCIENTIFIC SCORE
Possibly Effective
Based on 24 Researches
7.4
USERS' SCORE
Good
Based on 1 Reviews
8.8
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Vitamin A(60% as Beta-Carotene and 40% from Fish Liver Oil)
7,500 mcg
833%
Vitamin D3(as Cholecalciferol) (from Lanolin)
25 mcg (1,000 IU)
125%
Top Medical Research Studies
8
Vitamin D3 offers anti-cancer benefits
Liposomal encapsulation of cholecalciferol mitigates toxicity and delays tumor growth.
Study emphasizes isolated effects
We investigated the potential of vitamin D3, also known as cholecalciferol, in combating cancer while addressing concerns about its toxicity at higher doses. This study focused on enhancing the effectiveness of vitamin D3 through a clever method called liposomal encapsulation, which helps minimize side effects.
We prepared liposomal vitamin D3 (VD-LP) and conducted various tests to understand its capabilities. We found that this encapsulated form not only maintained high efficiency but also demonstrated improved stability. Our analyses showed that VD-LP had strong effects against cancer cells from colorectal, breast, and prostate cancers. Remarkably, it affected gene expression in immune cells, boosting elements that help fight infections and support the body's defenses.
Notably, VD-LP did a great job slowing tumor growth in mice and improved their survival rates without causing adverse effects like hypercalcemia, which is often a concern with regular vitamin D3 use. This evidence indicates that liposomal encapsulation of vitamin D3 could offer an effective cancer treatment strategy while minimizing unwanted side effects.
We believe this may pave the way for further research and clinical applications, showcasing vitamin D3 as a valuable addition to cancer therapy.
We prepared liposomal vitamin D3 (VD-LP) and conducted various tests to understand its capabilities. We found that this encapsulated form not only maintained high efficiency but also demonstrated improved stability. Our analyses showed that VD-LP had strong effects against cancer cells from colorectal, breast, and prostate cancers. Remarkably, it affected gene expression in immune cells, boosting elements that help fight infections and support the body's defenses.
Notably, VD-LP did a great job slowing tumor growth in mice and improved their survival rates without causing adverse effects like hypercalcemia, which is often a concern with regular vitamin D3 use. This evidence indicates that liposomal encapsulation of vitamin D3 could offer an effective cancer treatment strategy while minimizing unwanted side effects.
We believe this may pave the way for further research and clinical applications, showcasing vitamin D3 as a valuable addition to cancer therapy.
Read More
9
Vitamin D3 derivatives improve cancer treatment
Synthetic Studies on Vitamin D Derivatives with Diverse but Selective Biological Activities.
Highly relevant to cancer treatment
We focused on how modified forms of vitamin D3 can positively affect cancer treatment. The study revealed that a specific derivative, known as MART-10, demonstrated significant anti-tumor effects in mouse models. When administered at low doses, this compound showed robust anti-cancer activity against BxpC-3 cancer cells.
Additionally, we explored a new vitamin D analog, AH-1, which was found to enhance bone formation without the usual side effects associated with vitamin D treatments. This is particularly promising for osteoporosis patients. Another derivative named NS-74c even exhibited potent antagonist activity against the vitamin D receptor, indicating a potential for varied therapeutic uses.
Overall, our research highlighted the potential of vitamin D3 derivatives to tackle cancer while minimizing adverse effects. This approach opens new doors for therapeutic options in oncology, providing a glimpse into how modified vitamin D can improve treatment outcomes for patients.
Additionally, we explored a new vitamin D analog, AH-1, which was found to enhance bone formation without the usual side effects associated with vitamin D treatments. This is particularly promising for osteoporosis patients. Another derivative named NS-74c even exhibited potent antagonist activity against the vitamin D receptor, indicating a potential for varied therapeutic uses.
Overall, our research highlighted the potential of vitamin D3 derivatives to tackle cancer while minimizing adverse effects. This approach opens new doors for therapeutic options in oncology, providing a glimpse into how modified vitamin D can improve treatment outcomes for patients.
Read More
8
Vitamin D's potential in CRC
Exploration and Identification of Vitamin D and Related Genes as Potential Biomarkers for Colorectal Tumors.
High relevance to cancer treatment
We delved into the intriguing relationship between vitamin D and colorectal cancer (CRC) to uncover how this nutrient might influence cancer development and treatment. The study involved measuring the serum levels of active vitamin D (1,25(OH)D) in different groups, including those with normal conditions, colorectal adenomas (CRA), and colorectal cancer (CRC).
Our findings highlighted a significant drop in vitamin D levels in CRC patients, with levels falling to 19.00 µg/mL compared to 42.99 µg/mL in normal individuals. Additionally, we conducted bioinformatics analysis to pinpoint genes linked to vitamin D and colorectal cancer, testing these using HCT116 and HT29 cell lines.
We observed that vitamin D can inhibit the growth and spread of colon cancer cells, leading to a reduction in the activity of certain cancer-promoting genes. Interestingly, our analysis also showed that a diagnostic model based on five key vitamin D-related genes exhibited high diagnostic efficiency. This reveals vitamin D's potential as a supportive approach for CRC diagnosis and treatment, offering hope for improved cancer management.
Our findings highlighted a significant drop in vitamin D levels in CRC patients, with levels falling to 19.00 µg/mL compared to 42.99 µg/mL in normal individuals. Additionally, we conducted bioinformatics analysis to pinpoint genes linked to vitamin D and colorectal cancer, testing these using HCT116 and HT29 cell lines.
We observed that vitamin D can inhibit the growth and spread of colon cancer cells, leading to a reduction in the activity of certain cancer-promoting genes. Interestingly, our analysis also showed that a diagnostic model based on five key vitamin D-related genes exhibited high diagnostic efficiency. This reveals vitamin D's potential as a supportive approach for CRC diagnosis and treatment, offering hope for improved cancer management.
Read More
Most Useful Reviews
8.8
Improves mucous membranes
Being resistant to low thyroid means I require additional vitamin A. It aids all mucous membranes, alleviating slight incontinence, warding off coughs, and enhancing skin health. When paired with vitamin D, it also helps guard against cancer.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 24 Researches
7.4
9.5
Vitamin A shows promise in APL
Zebrafish modeling of atypical PML-RARA isoform from acute promyelocytic leukemia patient and its implications for clinical treatment.
Focus on ATRA's efficacy
We constructed a zebrafish model to explore how a unique version of the PML-RARA protein, linked to acute promyelocytic leukemia (APL), might respond to treatment with all-trans retinoic acid (ATRA). This model allowed us to examine whether ATRA, a derivative of vitamin A, could be effective for patients with atypical APL characteristics.
In our findings, we observed that the response of the new PML-RARA isoform to ATRA treatment was similar to classical isoforms seen in the condition. We also found that ATRA worked well in this model, leading to favorable results for the treated patient, who reached complete remission shortly after starting therapy with ATRA and arsenic trioxide (ATO).
These results highlight the promising potential of vitamin A derivatives in cancer treatment, especially in various forms of APL. It's encouraging to see that ATRA can lead to substantial recovery, further supporting its use in clinical settings alongside other therapies.
In our findings, we observed that the response of the new PML-RARA isoform to ATRA treatment was similar to classical isoforms seen in the condition. We also found that ATRA worked well in this model, leading to favorable results for the treated patient, who reached complete remission shortly after starting therapy with ATRA and arsenic trioxide (ATO).
These results highlight the promising potential of vitamin A derivatives in cancer treatment, especially in various forms of APL. It's encouraging to see that ATRA can lead to substantial recovery, further supporting its use in clinical settings alongside other therapies.
Read More
9.5
Promising APL treatment outcomes observed
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.
Combination treatment evaluated; ATRA included
We aimed to understand the effectiveness of a combination treatment involving all-trans retinoic acid (ATRA), arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) for patients with acute promyelocytic leukemia (APL). This was a phase 2 trial involving newly diagnosed APL patients, where ATRA and ATO were used to induce remission.
The results were promising, as we observed a complete remission rate of 93.8% among the participants. Furthermore, 97.1% of those who achieved remission had no measurable residual disease, indicating a strong initial response to the treatment regimen.
Over a median follow-up of about 62 months, the 5-year survival rates were also impressive, with event-free survival at 92.4%, disease-free survival at 93.6%, and overall survival at 93.1%. We noted some side effects, including elevated liver enzymes and infections, but there were no severe complications like veno-occlusive disease.
While the study highlights the benefits of ATRA in this combination treatment, we must clarify that we cannot specifically isolate the effect of vitamin A, as it was part of a broader therapeutic approach. Nonetheless, the combination of ATRA with other agents showed significant success in treating APL, reinforcing the importance of multifaceted cancer therapies.
The results were promising, as we observed a complete remission rate of 93.8% among the participants. Furthermore, 97.1% of those who achieved remission had no measurable residual disease, indicating a strong initial response to the treatment regimen.
Over a median follow-up of about 62 months, the 5-year survival rates were also impressive, with event-free survival at 92.4%, disease-free survival at 93.6%, and overall survival at 93.1%. We noted some side effects, including elevated liver enzymes and infections, but there were no severe complications like veno-occlusive disease.
While the study highlights the benefits of ATRA in this combination treatment, we must clarify that we cannot specifically isolate the effect of vitamin A, as it was part of a broader therapeutic approach. Nonetheless, the combination of ATRA with other agents showed significant success in treating APL, reinforcing the importance of multifaceted cancer therapies.
Read More
9
Fenretinide shows promise against AML
Fenretinide targets GATA1 to induce cytotoxicity in GATA1 positive Acute Erythroid and Acute Megakaryoblastic Leukemic cells.
Addresses targeted treatment in AML
We observed that certain types of Acute Myeloid Leukemia (AML), specifically acute erythroleukemia and acute megakaryocytic leukemia, have a concerningly short median survival and limited effective treatment options. Our exploration focused on understanding the role of the transcription factor GATA1, which is crucial for the survival of cells in these leukemia subtypes. Remarkably, we discovered that a compound known as Fenretinide (or 4-HPR), a synthetic derivative of vitamin A, can target and induce loss of GATA1 in these AML cells.
As we delved into the study, we found that treating M6 AML cells with low concentrations of 4-HPR led to significant cytotoxic effects, akin to reducing GATA1 levels through genetic methods. This indicates that 4-HPR could act similar to a targeted therapy, directly impacting the survival of these cancer cells. Further, we were encouraged to see that 4-HPR not only performed effectively on its own but also enhanced the effectiveness of existing treatments like Azacytidine and Venetoclax, which typically struggle against drug resistance.
Our findings suggest that 4-HPR might represent a promising therapeutic avenue for patients with M6 and M7 AML, paving the way for its potential inclusion as a standard treatment option in the near future. The safety profile of Fenretinide, established through numerous clinical trials, further strengthens the case for its application in the combat against these aggressive forms of leukemia.
As we delved into the study, we found that treating M6 AML cells with low concentrations of 4-HPR led to significant cytotoxic effects, akin to reducing GATA1 levels through genetic methods. This indicates that 4-HPR could act similar to a targeted therapy, directly impacting the survival of these cancer cells. Further, we were encouraged to see that 4-HPR not only performed effectively on its own but also enhanced the effectiveness of existing treatments like Azacytidine and Venetoclax, which typically struggle against drug resistance.
Our findings suggest that 4-HPR might represent a promising therapeutic avenue for patients with M6 and M7 AML, paving the way for its potential inclusion as a standard treatment option in the near future. The safety profile of Fenretinide, established through numerous clinical trials, further strengthens the case for its application in the combat against these aggressive forms of leukemia.
Read More
9
Acyclic Retinoid aids lung cancer treatment
Acyclic Retinoid Inhibits the EGFR/AKT Signaling Pathway and Cancels Cisplatin-resistant Cell Characteristics.
Moderate relevance; vitamin A context
This study delved into the effects of a compound called Acyclic Retinoid, which is derived from vitamin A, on lung cancer and its resistance to a common chemotherapy drug, cisplatin. We explored how Acyclic Retinoid could impact key signaling pathways that contribute to the growth and spread of non-small cell lung cancer (NSCLC), a prevalent and deadly form of the disease. Our focus was on how ACR affected the signals associated with the cancer progression, particularly the EGFR/AKT pathway, which is often overactive in lung cancer situations.
We treated various types of lung cells—including standard cancer cell lines and those resistant to cisplatin—with ACR, both alone and alongside cisplatin. By examining cell viability, apoptosis (the process of programmed cell death), and changes in important cellular signals, we gathered insightful data on the potential of this treatment. The results were promising; ACR inhibited the EGFR/AKT signaling pathway and showed an ability to improve the effectiveness of cisplatin against NSCLC and its resistant variants.
Overall, we observed that Acyclic Retinoid may hold significant promise as a therapeutic strategy for lung cancer, particularly for those patients who have developed resistance to traditional treatments. Its capability to enhance the effects of existing chemotherapy options could lead to better outcomes for patients battling this challenging disease.
We treated various types of lung cells—including standard cancer cell lines and those resistant to cisplatin—with ACR, both alone and alongside cisplatin. By examining cell viability, apoptosis (the process of programmed cell death), and changes in important cellular signals, we gathered insightful data on the potential of this treatment. The results were promising; ACR inhibited the EGFR/AKT signaling pathway and showed an ability to improve the effectiveness of cisplatin against NSCLC and its resistant variants.
Overall, we observed that Acyclic Retinoid may hold significant promise as a therapeutic strategy for lung cancer, particularly for those patients who have developed resistance to traditional treatments. Its capability to enhance the effects of existing chemotherapy options could lead to better outcomes for patients battling this challenging disease.
Read More
9
Vitamin A combined with SM effective
Combinational therapy of all-trans retinoic acid (ATRA) and sphingomyelin induces apoptosis and cell cycle arrest in B16F10 melanoma cancer cells.
Study relevance moderate
We explored the potential of all-trans retinoic acid (ATRA), a derivative of vitamin A, in treating melanoma. In our study, we combined ATRA with sphingomyelin (SM) to see if this pairing could enhance its effectiveness against aggressive melanoma cells.
We focused on an in vitro model using B16F10 melanoma cells and assessed how well this combination could promote cell death and stop the cells from growing. Our results highlighted that the combination of 123 μM of ATRA with 136 μM of SM was particularly effective, leading to a dramatic reduction in cell proliferation and significant apoptotic cell death.
This combination not only increased the expression of key genes that promote cell death, but it also caused a halt in the cell cycle, preventing cancer cells from continuing to grow. Moreover, our findings suggest that using ATRA alongside SM may provide a promising avenue for melanoma treatment while minimizing harm to normal, healthy cells.
We focused on an in vitro model using B16F10 melanoma cells and assessed how well this combination could promote cell death and stop the cells from growing. Our results highlighted that the combination of 123 μM of ATRA with 136 μM of SM was particularly effective, leading to a dramatic reduction in cell proliferation and significant apoptotic cell death.
This combination not only increased the expression of key genes that promote cell death, but it also caused a halt in the cell cycle, preventing cancer cells from continuing to grow. Moreover, our findings suggest that using ATRA alongside SM may provide a promising avenue for melanoma treatment while minimizing harm to normal, healthy cells.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Reviews
8.8
8.8
Improves mucous membranes
Being resistant to low thyroid means I require additional vitamin A. It aids all mucous membranes, alleviating slight incontinence, warding off coughs, and enhancing skin health. When paired with vitamin D, it also helps guard against cancer.
